The Lupus Research Alliance announced that Lupus Therapeutics has partnered with Novartis Pharmaceuticals to launch three new phase III clinical trials evaluating the safety and efficacy of the novel monoclonal antibody ianalumab in patients with systemic lupus erythematosus and lupus nephritis. In the new trials—SIRIUS-LN, SIRIUS-SLE 1, and SIRIUS-SLE 2—researchers will assign patients to receive either ianalumab or placebo delivered through subcutaneous injection once monthly or once every 3 months. The researchers hope their findings can improve patient outcomes and accelerate the development of novel lupus treatments. Lupus Therapeutics noted that all three trials are currently open for enrollment.
June 09, 2023